Press releases

2017-11-02 – Press release

Topas Therapeutics extends its Series A to EUR 18 Million (USD 21 Million) with Boehringer Ingelheim Venture Fund

Corporate venture fund invests EUR 4 million (USD 5 million) into Topas
Financing to accelerate clinical trials in autoimmune diseases
Detlev Mennerich, Ph.D., Investment Manager of BIVF, to join Topas’ Board ofDirectors

2017-10-26 – Press release

Topas Therapeutics Appoints Rupert Sandbrink, M.D., Ph.D., as Chief Development Officer and Chief Medical Officer

Highly accomplished pharmaceutical executive with many years of clinical development, medical affairs, and regulatory experience at Bayer and Schering
To lead Topas’ clinical development and regulatory affairs

2017-08-22 – Press release

Topas Therapeutics signs multi-year research and option agreement with Lilly focused on immune tolerance

2017-04-04 – Press release

Paul Sekhri joins Topas Therapeutics as Chairman of the Board

2016-03-22 – Press release

Evotec spins off auto-immune disease company as ‘Topas Therapeutics GmbH’

Topas Therapeutics GmbH is based on a proprietary nanoparticle platform which supports antigen-specific tolerance induction for multiple indications
Strong consortium consisting of Epidarex Capital, EMBL Ventures, Gimv and Evotec AG supports strategic Series A financing round of EUR 14 m
Initiation of first clinical trials expected in 2017